Journal profile · Oncology
Chinese Journal of Cancer Research
ISSN 1000-9604 · eISSN 1993-0631 · Springer Berlin Heidelberg · PEOPLES R CHINA · Quarterly · Founded 1988
Chinese Journal of Cancer Research: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 6.6; fully open access; median 73 days to acceptance (96 articles, last 24 months); community-reported acceptance: about 62.5%; 80 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Chinese Journal of Cancer Research is published by Springer Berlin Heidelberg and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Gastric Cancer Management and Outcomes, Cancer-related Molecular Pathways and Esophageal Cancer Research and Treatment, together about 20.4% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Chinese Journal of Cancer Research (CJCR; Print ISSN: 1000-9604; Online ISSN:1993-0631; www.thecjcr.org) is published by AME Publishing Company (www.amepc.org) in association with Chinese Anti-Cancer Association.It was launched in March 1995 as a quarterly publication and is now published bi-monthly since February 2013. CJCR is published bi-monthly in English, and is an international journal devoted to the life sciences and medical sciences. It publishes peer-reviewed original articles of basic investigations and clinical observations, reviews and brief communications providing a forum for the recent experimental and clinical advances in cancer research. This journal is indexed in Science Citation Index Expanded (SCIE), PubMed/PubMed Central (PMC), Scopus, SciSearch, Chemistry Abstracts (CA), the Excerpta Medica/EMBASE, Chinainfo, CNKI, CSCI, etc.
Source: LetPub
Research area (LetPub): Oncology
Main research topics OpenAlex counts of recent articles; shares are approximate
- Gastric Cancer Management and OutcomesMedicine9.9%
- Cancer-related Molecular PathwaysMedicine5.5%
- Esophageal Cancer Research and TreatmentMedicine5.1%
- Lung Cancer Treatments and MutationsMedicine4.7%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology4.4%
- Immunotherapy and Immune ResponsesImmunology and Microbiology4.3%
- Hepatocellular Carcinoma Treatment and PrognosisMedicine4%
- Cancer Research and TreatmentsBiochemistry, Genetics and Molecular Biology4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 6.6LetPub ·
- CiteScore 2026-06
- 7.9LetPub ·
- SJR 2026-06
- 1.41LetPub ·
- SNIP 2026-06
- 1.17LetPub ·
- h-index
- 62OpenAlex ·
- i10-index
- 502OpenAlex ·
- 2-year mean citedness
- 5.57OpenAlex ·
- Self-citation rate
- 14.9%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 66LetPub ·
Articles by year OpenAlex count · 2,254 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 47 | 47 | 10 |
| 2025 | 80 | 80 | 469 |
| 2024 | 56 | 56 | 541 |
| 2023 | 56 | 56 | 949 |
| 2022 | 60 | 60 | 1,142 |
| 2021 | 64 | 64 | 1,715 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
73 daysMedian, submission to acceptance · P25–P75 25 days – 97 days
- Acceptance to online
- —
- Submission to online
- —
- Sample
- 96 articles with submission and acceptance dates (149 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 4.5 monthsLetPub ·
- Average acceptance (community reports)
- 62.5%LetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessOpenAlex
Every article is open access; authors usually pay an article processing charge (APC).
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Springer Berlin Heidelberg
- Country or region
- PEOPLES R CHINA
- Language
- English
- Frequency
- Quarterly
- Founded
- 1988
- ISSN
- 1000-9604
- Electronic ISSN
- 1993-0631
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Chinese Journal of Cancer Research
What CAS zone is Chinese Journal of Cancer Research in?
In the 2025 upgraded edition of the CAS Journal Ranking, Chinese Journal of Cancer Research is in Zone 2 of Medicine, and in Zone 3 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Chinese Journal of Cancer Research?
The latest impact factor listed by LetPub is 6.6; CiteScore 7.9, h-index 62.
How long does peer review take at Chinese Journal of Cancer Research?
Based on the dates recorded on 96 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 73 days (interquartile range 25–97 days); authors report an average review time of about 4.5 months; the community-reported acceptance is “about 62.5%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Chinese Journal of Cancer Research?
According to LetPub and DOAJ records, Chinese Journal of Cancer Research is indexed in SCIE and Scopus.
Is Chinese Journal of Cancer Research open access, and what is the APC?
Chinese Journal of Cancer Research is a fully open-access journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .